Meixiao Long, MD, PhDThe James Cancer Center
As a hematologist-oncologist, I have a special interest in treating patients with chronic lymphocytic leukemia (CLL). My research focus has been on developing novel therapeutics that will boost the patient’s immune system to naturally fight the disease. Presently, I’m clinical instructor in hematology-oncology at The Ohio State University.
I received my clinical medical training at the China Medical University, followed by a doctorate in biomedical sciences from the University of Connecticut. Later I completed additional training in immunology from Yale and Columbia University, and my internal medicine residency from the University of Texas.
I’ve been involved in several long-term research projects with the latest here at Ohio State under Dr. John Byrd’s direction. We are studying the immune modulatory effects of small molecule kinase inhibitors and their potential for immunotherapy. It’s our hope that our research will lead to better treatments and, ultimately, a cure.
All of us here at the OSUCCC – James are dedicated to fighting cancer. Virtually everyone knows somebody who’s been impacted by cancer, and we’re no exception. That’s why we’re committed to providing excellent care of our patients as we search for answers and cures that will prolong lives.
Education and Background
China Medical University
University of Texas Southwestern
The First Affiliated Hospital
Ohio State University Wexner Medical Center
- American Board of Internal Medicine
- American Board of Internal Medicine (Subspecialty: Hematology)
- American Board of Internal Medicine (Subspecialty: Medicine Oncology)
- Department of Internal Medicine
- Division of Hematology
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 3/28/2017, Dr. Long has reported no financial relationships with medical device, research and/or drug companies.